Alteration in methylation level at 11β-hydroxysteroid dehydrogenase type 2 gene promoter in infants born to preeclamptic women

BMC Genetics

Hefeng Huang¹  Wenjuan Li¹  Yun Liu²  Minyue Dong¹  Xiaoling Weng³  Wensheng Hu¹ 

[1] Women’s Hospital, School of Medicine, Zhejiang University, 1 Xueshi Road, Hangzhou 310006, Zhejiang Province, China;Key Laboratory of Molecular Medicine, The Ministry of Education, Department of Biochemistry and Molecular Biology, Fudan University, 220 Handan Road, Shanghai, China;Institutes of Biomedical Sciences, Fudan University, 220 Handan Road, Shanghai, China

关键词: Metabolic diseases;    HSD11B2;    Promoter;    DNA methylation;    Offspring;    Preeclampsia;   

Others  :  1085618
DOI  :  10.1186/s12863-014-0096-5

 received in 2014-06-11, accepted in 2014-08-26,  发布年份 2014

【 摘 要 】

Background

Preeclampsia reduces placental expression and activity of 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2), leading to an increase in fetal glucocordicoids. The latter has been proposed to be associated with low birth weight and high risk of metabolic diseases in later life of the offspring. This investigation aims to delineate the alteration in methylation levels at CpG sites of HSD11B2 promoter.

Results

Methylation levels of HSD9-2, HSD9-3, HSD23-2 and HSD23-3 and the mean methylation level were significantly lower in preeclampsia than in normal pregnancy (P = 0.002, 0.031, 0.047 and 0.001, respectively and P < 0.001 in mean). The mean methylation level was significantly correlated with preeclampsia after the adjustment of birth weight, maternal age, gestational age at delivery and fetal gender (r = 0.325, P < 0.001).

Conclusions

Preeclampsia reduced methylation level at fetal HSD11B2 promoter. A positive correlation existed between HSD11B2 promoter methylation and preeclampsia. Our findings suggest that the methyaltion status of HSD11B2 promoter is a potentially accessible biomarker for preeclampsia. However, further studies are required to address the mechanisms of thehypomethylation at HSD11B2 promoter and the significance of the hypomethylation in the development of metabolic diseases of the fetals born to preeclamptic women.

【 授权许可】

   
2014 Hu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy.Am J Obstet Gynecol 2000, 183:S1–S22.
• [2]Rich-Edwards JW, Grizzard TA: Psychosocial stress and neuroendocrine mechanisms in preterm delivery. Am J Obstet Gynecol 2005, 192:S30-S35.
• [3]Curhan GC, Chertow GM, Willett WC, Spiegelman D, Colditz GA, Colditz GA, Manson JE, Speizer FE, Stampfer MJ: Birth weight and adult hypertension and obesity in women. Circulation 1996, 94:1310-1315.
• [4]Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM: Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993, 36:62-67.
• [5]Serman L, Vlahovic M, Sijan M, Bulic-Jakus F, Serman A, Sincic N, Matijevic R, Juric-Lekic G, Katusic A: The impact of 5-azacytidine on placental weight, glycoprotein pattern and proliferating cell nuclear antigen expression in rat placenta. Placenta 2007, 28:803-811.
• [6]He J, Zhang A, Fang M, Fang R, Ge J, Jiang Y, Zhang H, Han C, Ye X, Yu D, Huang H, Liu Y, Dong M: Methylation levels at IGF2 and GNAS DMRs in infants born to preeclamptic pregnancies.BMC Genomics 2013, 14:472.
• [7]ACOG practice bulletin. Management of infertility caused by ovulatory dysfunction. Number 34, February 2002. American College of Obstetricians and Gynecologists Int J Gynaecol Obstet 2002, 77:177-188.
• [8]Schoof E, Girstl M, Frobenius W, Kirschbaum M, Dorr HG, Rascher W, Dotsch J: Decreased gene expression of 11beta-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprostaglandin dehydrogenase in human placenta of patients with preeclampsia. J Clin Endocrinol Metab 2001, 86:1313-1317.
• [9]He P, Chen Z, Sun Q, Li Y, Gu H, Ni X: Reduced expression of 11beta-hydroxysteroid dehydrogenase type 2 in preeclamptic placentas is associated with decreased PPARgamma but increased PPARalpha expression. Endocrinology 2014, 155:299-309.
• [10]Hardy DB, Yang K: The expression of 11 beta-hydroxysteroid dehydrogenase type 2 is induced during trophoblast differentiation: effects of hypoxia. J Clin Endocrinol Metab 2002, 87:3696-3701.
• [11]Alfaidy N, Gupta S, DeMarco C, Caniggia I, Challis JR: Oxygen regulation of placental 11 b-hydroxysteroid dehydrogenase 2: physiological and pathological implications. J Clin Endocrinol 2002, 87:4797-4805.
• [12]Benediktsson R, Calder AA, Edwards CR, Seckl JR: Placental 11b-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf) 1997, 46:161-166.
• [13]Goland RS, Jozak S, Warren WB, Conwell IM, Stark RI, Tropper PJ: Elevated levels of umbilical cord plasma corticotropin-releasing hormone in growth-retarded fetuses. J Clin Endocrinol Metab 1993, 77:1174-1179.
• [14]Goland RS, Tropper PJ, Warren WB, Stark RI, Jozak SM, Conwell IM: Concentrations of corticotrophin-releasing hormone in the umbilical-cord blood of pregnancies complicated by pre-eclampsia. Reprod Fertil Dev 1995, 7:1227-1230.
• [15]Seckl JR, Meaney MJ: Glucocorticoid programming. Ann N Y Acad Sci 2004, 1032:63-84.
• [16]Meaney MJ, Szyf M, Seckl JR: Epigenetic mechanisms of perinatal programming of hypothalamic-pituitary-adrenal function and health. Trends Mol Med 2007, 13:269-277.
• [17]Jaquiery AL, Oliver MH, Bloomfield FH, Connor KL, Challis JR, Harding JE: Fetal exposure to excess glucocorticoid is unlikely to explain the effects of periconceptional undernutrition in sheep. J Physiol 2006, 572:109-118.
• [18]Dave-Sharma S, Wilson RC, Harbison MD, Newfield R, Azar MR, Krozowski ZS, Funder JW, Shackleton CH, Bradlow HL, Wei JQ, Hertecant J, Moran A, Neiberger RE, Balfe JW, Fattah A, Daneman D, Akkurt HI, De Santis C, New MI: Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol 1998, 83:2244-2254.
• [19]Blasco MJ, Lopez Bernal A, Turnbull AC: 11 beta-Hydroxysteroid dehydrogenase activity of the human placenta during pregnancy. Horm Metab Res 1986, 18:638-641.
• [20]Stewart PM, Murry BA, Mason JI: Type 2 11 beta-hydroxysteroid dehydrogenase in human fetal tissues. J Clin Endocrinol Metab 1994, 78:1529-1532.
• [21]Brown RW, Chapman KE, Kotelevtsev Y, Yau JL, Lindsay RS, Brett L, Leckie C, Murad P, Lyons V, Mullins JJ, Edwards CR, Seckl JR: Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2. Biochem J 1996, 313(Pt 3):1007-1017.
• [22]Zhao Y, Gong X, Chen L, Li L, Liang Y, Chen S, Zhang Y: Site-specific methylation of placental HSD11B2 gene promoter is related to intrauterine growth restriction. Eur J Hum Genet 2014, 22:734-740.
• [23]Lanz B, Kadereit B, Ernst S, Shojaati K, Causevic M, Frey BM, Frey FJ, Mohaupt MG: Angiotensin II regulates 11beta-hydroxysteroid dehydrogenase type 2 via AT2 receptors. Kidney Int 2003, 64:970-977.
• [24]Heiniger CD, Kostadinova RM, Rochat MK, Serra A, Ferrari P, Dick B, Frey BM, Frey FJ: Hypoxia causes down-regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1. FASEB J 2003, 17:917-919.
• [25]Lanz CB, Causevic M, Heiniger C, Frey FJ, Frey BM, Mohaupt MG: Fluid shear stress reduces 11ss-hydroxysteroid dehydrogenase type 2. Hypertension 2001, 37:160-169.
• [26]Kossintseva I, Wong S, Johnstone E, Guilbert L, Olson DM, Mitchell BF: Proinflammatory cytokines inhibit human placental 11beta-hydroxysteroid dehydrogenase type 2 activity through Ca2+ and cAMP pathways. Am J Physiol Endocrinol Metab 2006, 290:E282-E288.
• [27]Campino C, Carvajal CA, Cornejo J, San Martin B, Olivieri O, Guidi G, Faccini G, Pasini F, Sateler J, Baudrand R, Mosso L, Owen GI, Kalergis AM, Padilla O, Fardella CE: 11beta-Hydroxysteroid dehydrogenase type-2 and type-1 (11beta-HSD2 and 11beta-HSD1) and 5beta-reductase activities in the pathogenia of essential hypertension. Endocrine 2010, 37:106-114.
• [28]Agalou S, Butt AN, Chowienczyk P, Swaminathan R: Hypertension and circulating mRNA for 11beta-hydroxysteroid dehydrogenase type II. Ann N Y Acad Sci 2008, 1137:290-295.
• [29]Friso S, Pizzolo F, Choi SW, Guarini P, Castagna A, Ravagnani V, Carletto A, Pattini P, Corrocher R, Olivieri O: Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis 2008, 199:323-327.